This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MGEN vs. OPGN, ENZ, PROK, LXRX, FHTX, QTRX, TNXP, MXCT, AARD, and ESPRShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include OpGen (OPGN), Enzo Biochem (ENZ), ProKidney (PROK), Lexicon Pharmaceuticals (LXRX), Foghorn Therapeutics (FHTX), Quanterix (QTRX), Tonix Pharmaceuticals (TNXP), MaxCyte (MXCT), Aardvark Therapeutics (AARD), and Esperion Therapeutics (ESPR). These companies are all part of the "medical" sector. Miragen Therapeutics vs. Its Competitors OpGen Enzo Biochem ProKidney Lexicon Pharmaceuticals Foghorn Therapeutics Quanterix Tonix Pharmaceuticals MaxCyte Aardvark Therapeutics Esperion Therapeutics Miragen Therapeutics (NASDAQ:MGEN) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk. Which has stronger valuation & earnings, MGEN or OPGN? OpGen has lower revenue, but higher earnings than Miragen Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiragen Therapeutics$4.46M12.90-$41.87M-$20.09-0.73OpGen$2.67M18.38-$32.67MN/AN/A Do institutionals & insiders believe in MGEN or OPGN? 2.7% of OpGen shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by insiders. Comparatively, 43.8% of OpGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer MGEN or OPGN? In the previous week, OpGen had 1 more articles in the media than Miragen Therapeutics. MarketBeat recorded 1 mentions for OpGen and 0 mentions for Miragen Therapeutics. OpGen's average media sentiment score of 1.00 beat Miragen Therapeutics' score of 0.00 indicating that OpGen is being referred to more favorably in the news media. Company Overall Sentiment Miragen Therapeutics Neutral OpGen Positive Which has more volatility and risk, MGEN or OPGN? Miragen Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, OpGen has a beta of -1.68, indicating that its share price is 268% less volatile than the S&P 500. Does the MarketBeat Community favor MGEN or OPGN? OpGen received 34 more outperform votes than Miragen Therapeutics when rated by MarketBeat users. However, 70.45% of users gave Miragen Therapeutics an outperform vote while only 51.81% of users gave OpGen an outperform vote. CompanyUnderperformOutperformMiragen TherapeuticsOutperform Votes26770.45% Underperform Votes11229.55% OpGenOutperform Votes30151.81% Underperform Votes28048.19% Is MGEN or OPGN more profitable? OpGen has a net margin of -1,140.36% compared to Miragen Therapeutics' net margin of -1,393.50%. OpGen's return on equity of 0.00% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Miragen Therapeutics-1,393.50% -141.66% -88.74% OpGen -1,140.36%N/A -287.58% SummaryOpGen beats Miragen Therapeutics on 9 of the 13 factors compared between the two stocks. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.53M$22.46M$5.20B$8.59BDividend YieldN/A119.72%5.38%4.19%P/E Ratio-1.38N/A25.4319.11Price / Sales12.906.93397.95101.34Price / CashN/AN/A35.5255.99Price / Book2.170.217.975.79Net Income-$41.87M-$27.15M$3.15B$248.74M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$14.72-1.9%N/A+23.2%$57.53M$4.46M-1.3845High Trading VolumeOPGNOpGenN/A$4.88-0.4%N/A+106.8%$49.13M$2.67M0.00100Positive NewsShort Interest ↓Gap DownHigh Trading VolumeENZEnzo BiochemN/A$0.33-14.8%N/A-70.5%$17.03M$29.09M0.00520News CoverageGap DownHigh Trading VolumePROKProKidney1.6861 of 5 stars$0.86-13.0%$4.50+424.5%-74.2%$245.37M$80K-1.433Gap UpLXRXLexicon Pharmaceuticals2.6539 of 5 stars$0.72+7.6%$3.67+408.8%-57.1%$242.74M$31.08M-1.41140FHTXFoghorn Therapeutics1.7133 of 5 stars$4.79+9.1%$12.13+153.1%-9.9%$240.80M$22.60M0.00120QTRXQuanterix3.2817 of 5 stars$6.14-0.5%$15.60+154.1%-54.4%$235.31M$137.42M-4.72460Positive NewsTNXPTonix Pharmaceuticals3.0177 of 5 stars$34.92-5.5%$585.00+1,575.3%-76.0%$235.28M$10.09M-0.0250MXCTMaxCyte3.1072 of 5 stars$2.15-4.0%$7.50+248.8%-51.0%$234.12M$38.63M0.0080AARDAardvark TherapeuticsN/A$11.27+3.9%$31.25+177.3%N/A$233.01MN/A0.0018High Trading VolumeESPREsperion Therapeutics4.0985 of 5 stars$1.09-6.8%$6.25+473.4%-53.3%$231.89M$332.31M-1.36200Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies OpGen Alternatives Enzo Biochem Alternatives ProKidney Alternatives Lexicon Pharmaceuticals Alternatives Foghorn Therapeutics Alternatives Quanterix Alternatives Tonix Pharmaceuticals Alternatives MaxCyte Alternatives Aardvark Therapeutics Alternatives Esperion Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGEN) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGEN Stock Free MGEN Stock Alerts